Catherine E. Berry
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.
Journal: Nature communications
Published: February 05, 2026
Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients.
Journal: Scientific reports
Published: December 07, 2025
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 16, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Journal: The New England journal of medicine
Published: January 29, 2025
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.
Journal: The European respiratory journal
Published: December 07, 2024
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
Journal: Antimicrobial agents and chemotherapy
Published: June 06, 2024
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort.
Journal: PLOS global public health
Published: April 04, 2024
Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 29, 2024
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation.
Journal: The Lancet. Global health
Published: January 05, 2024
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Journal: The Lancet. Respiratory medicine
Published: September 01, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 19, 2023
Last Updated: 09/26/2026